9-Jan-2026
PRNewswire (Thu, 8-Jan 11:51 AM ET)
PRNewswire (Wed, 7-Jan 5:13 PM ET)
PRNewswire (Tue, 23-Dec 6:56 PM ET)
Business Wire (Tue, 16-Dec 8:08 AM ET)
PRNewswire (Thu, 11-Dec 8:54 PM ET)
Business Wire (Tue, 2-Dec 8:10 AM ET)
New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA
Business Wire (Tue, 25-Nov 8:08 AM ET)
Halper Sadeh LLC Encourages FRGE, BHF, HOLX Shareholders to Contact the Firm to Discuss Their Rights
Globe Newswire (Sat, 22-Nov 5:14 AM ET)
PRNewswire (Fri, 21-Nov 5:30 PM ET)
PRNewswire (Fri, 14-Nov 3:19 PM ET)
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Hologic trades on the NASDAQ stock market under the symbol HOLX.
As of January 9, 2026, HOLX stock price declined to $74.87 with 1,825,125 million shares trading.
HOLX has a beta of 0.10, meaning it tends to be less sensitive to market movements. HOLX has a correlation of 0.01 to the broad based SPY ETF.
HOLX has a market cap of $16.69 billion. This is considered a Large Cap stock.
Last quarter Hologic reported $1 billion in Revenue and $1.13 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.03.
In the last 3 years, HOLX traded as high as $87.88 and as low as $51.90.
The top ETF exchange traded funds that HOLX belongs to (by Net Assets): VTI, VOO, VB, VBR, IVV.
HOLX has underperformed the market in the last year with a price return of +2.9% while the SPY ETF gained +19.0%. However, in the short term, HOLX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.1% vs +3.7% return in SPY. But in the last 2 weeks, HOLX shares have been beat by the market, returning +0.5% compared to an SPY return of +0.5%.
HOLX support price is $74.73 and resistance is $75.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HOLX shares will trade within this expected range on the day.
